Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias

Giovanni Bellomo, Lisa Vermunt, Marta del Campo

1. 01

   Large multicentre plasma proteomics cohort spanning AD, DLB and FTD

2. 02

   Identified protein signatures that discriminate between neurodegenerative syndromes, not just disease versus control

3. 03

   Signatures also supported molecular staging within disease

4. 04

   Extends blood-based neurodegeneration testing beyond amyloid/tau-centric single analytes

Study Design

Cohort Study

Sample Size

Not reported

Study Duration

Not reported

Methodology

Multicentre plasma proteomic profiling across clinically and biomarker-characterised neurodegenerative dementia cohorts with discrimination and staging analyses.

Limitations

Assay standardisation across platforms and prospective validation in unselected memory-clinic populations remain outstanding. Cohort-based discrimination performance typically overstates real-world performance where pre-test probability and comorbidity differ. Not yet a clinically deployable panel.